You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 9,629,861

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,629,861

Title:	Compositions and methods for treating bacterial infections using ceftaroline
Abstract:	The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).
Inventor(s):	Thye; Dirk (San Francisco, CA), Talbot; George (Wayne, PA)
Assignee:	FOREST LABORATORIES HOLDING LIMITED (Hamilton, BM)
Application Number:	14/722,495
Patent Claims:	1. A pharmaceutical composition comprising ceftaroline or a prodrug thereof for treatment of a bacterial infection wherein the composition comprises from about 200 mg to about 800 mg of the ceftaroline or prodrug thereof, and an amount of the L-arginine adduct of formula I: ##STR00015## wherein said amount is less than about 2% of said pharmaceutical composition. 2. A pharmaceutical composition comprising ceftaroline or a prodrug thereof for treatment of a bacterial infection wherein the composition comprises from about 200 mg to about 800 mg of the ceftaroline or product thereof, and an amount of the L-arginine adduct of formula II: ##STR00016## wherein said amount is less than about 2% of said pharmaceutical composition. 3. The composition of claim 1 or 2, wherein the bacterial infection is selected from the group consisting of complicated skin and skin structure infection and community-acquired bacterial pneumonia. 4. The composition of claim 1 or 2, wherein the ceftaroline or prodrug thereof is ceftaroline fosamil. 5. The composition of claim 1 or 2, wherein the bacterial infection is a complicated skin and skin structure infection. 6. The composition of claim 5, wherein the complicated skin and skin structure infection is due to a microorganism selected from the group consisting of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca and Morganella morganii. 7. The composition of claim 1 or 2, wherein the bacterial infection is community-acquired bacterial pneumonia. 8. The composition of claim 7, wherein the community-acquired bacterial pneumonia is due to a microorganism selected from the group consisting of Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae and Escherichia coli.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.